Skip to main content
Top
Published in: Pathology & Oncology Research 2/2012

01-04-2012 | Research

Investigation of β-catenin and E-cadherin Expression in Dukes B2 Stage Colorectal Cancer with Tissue Microarray Method. Is It a Marker of Metastatic Potential in Rectal Cancer?

Authors: László Tóth, Csilla András, Csaba Molnár, Miklós Tanyi, Zoltán Csiki, Péter Molnár, János Szántó

Published in: Pathology & Oncology Research | Issue 2/2012

Login to get access

Abstract

β-catenin and E cadherin are both membrane-associated proteins which are essential regulators and providers of cellular adhesion. In the metastatic cascade of malignant tumours, detachment of tumour cells from each other is a very important step. It has been shown in several tumour types, that reduced expression of these proteins is important. The aim of our study was to clarify the expression profile of these proteins, and correlate the findings with the metastasizing potential of early stage colon and rectal cancers. Formalin fixed and paraffin embedded samples from 79 Dukes B2 stage colorectal cancer were examined using a tissue microarray approach. The expression of β-catenin and E-cadherin proteins was determined immunohistochemically. Our findings indicated that there is a tendency for metastatic spread in cases when membranous expression of β-catenin is lost (p = 0.062). Similarly metastases in negative cases developed more rapidly, than in positive ones (p = 0.05). Survival rate was worse in the negative cases. The risk of metastasis in rectal cancer was significantly higher in the β-catenin membranously negative than positive groups (p = 0.024) and in case of β-catenin nuclear expression the risk was also higher (p = 0.047). Reduced E-cadherin expression also correlated with development of metastatic disease, but this association was statistically not significant. The immunohistochemical analysis of 79 cases shows that in Dukes B2 stage colorectal tumours clarification of β-catenin and E-cadherin expression patterns is reliable for predicting the metastatic potential of early stage rectal cancer and hence the method may have relevant implications in the therapeutic management of these cancers.
Literature
1.
2.
go back to reference Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026–1038PubMedCrossRef Graziano F, Cascinu S (2003) Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes B colorectal cancer patients: how much evidence is enough? Ann Oncol 14:1026–1038PubMedCrossRef
3.
go back to reference Iqbal S, Stoehlmacher J, Lenz HJ (2004) Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22:762–773PubMedCrossRef Iqbal S, Stoehlmacher J, Lenz HJ (2004) Tailored chemotherapy for colorectal cancer: a new approach to therapy. Cancer Invest 22:762–773PubMedCrossRef
4.
go back to reference Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354PubMed Stoehlmacher J, Park DJ, Zhang W et al (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354PubMed
5.
go back to reference Tsanou E, Peschos D, Batistatou A et al (2008) The E-cadherin adhaesion molecule and colorectal cancer. A global literature approach. Anticancer Res 28:3815–3826PubMed Tsanou E, Peschos D, Batistatou A et al (2008) The E-cadherin adhaesion molecule and colorectal cancer. A global literature approach. Anticancer Res 28:3815–3826PubMed
6.
go back to reference Kikuchi A (2000) Regulation of β-catenin signalling in the Wnt pathway. Biochem Bioph Res Co 268:243–248CrossRef Kikuchi A (2000) Regulation of β-catenin signalling in the Wnt pathway. Biochem Bioph Res Co 268:243–248CrossRef
7.
go back to reference Lugli A, Zlobec I, Minoo P et al (2007) Prognotic significance of the wnt signalling patway molecules APC, β-catenin and E-cadherin in colorectal cancer—a tissue microarray based analysis. Histopathology 50:453–464PubMedCrossRef Lugli A, Zlobec I, Minoo P et al (2007) Prognotic significance of the wnt signalling patway molecules APC, β-catenin and E-cadherin in colorectal cancer—a tissue microarray based analysis. Histopathology 50:453–464PubMedCrossRef
8.
go back to reference Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426PubMedCrossRef Tetsu O, McCormick F (1999) β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426PubMedCrossRef
9.
go back to reference Ikeda S, Kishida S, Yamamoto H et al (1998) Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3 beta and β-catenin and promotes GSK3 beta dependent phosphorylation of β-catenin. EMBO J 17:1371–1384PubMedCrossRef Ikeda S, Kishida S, Yamamoto H et al (1998) Axin, a negative regulator of the Wnt signalling pathway, forms a complex with GSK-3 beta and β-catenin and promotes GSK3 beta dependent phosphorylation of β-catenin. EMBO J 17:1371–1384PubMedCrossRef
10.
go back to reference Chen S, Liu J, Li G et al (2008) Altered distribution of β-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol 43:456–464PubMedCrossRef Chen S, Liu J, Li G et al (2008) Altered distribution of β-catenin and prognostic roles in colorectal carcinogenesis. Scand J Gastroenterol 43:456–464PubMedCrossRef
11.
go back to reference Han SA, Chun H, Park CM et al (2006) Prognostic significance of β-catenin in colorectal cancer with liver metastasis. Clin Oncol 18:761–767CrossRef Han SA, Chun H, Park CM et al (2006) Prognostic significance of β-catenin in colorectal cancer with liver metastasis. Clin Oncol 18:761–767CrossRef
12.
go back to reference Horst D, Reu S, Kriegl L et al (2009) The intratumoral distribution of nuclear β-catenin is a prognostic marker in colon cancer. Cancer 115:2063–2070PubMedCrossRef Horst D, Reu S, Kriegl L et al (2009) The intratumoral distribution of nuclear β-catenin is a prognostic marker in colon cancer. Cancer 115:2063–2070PubMedCrossRef
13.
go back to reference Battifora H (1986) The multitumor (sausage) tissue block: Novel method for immunhistochemical antibody testing. Lab Invest 55:244–248PubMed Battifora H (1986) The multitumor (sausage) tissue block: Novel method for immunhistochemical antibody testing. Lab Invest 55:244–248PubMed
14.
go back to reference Fernebro E, Dictor M, Bendhal P et al (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702–705PubMed Fernebro E, Dictor M, Bendhal P et al (2002) Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126:702–705PubMed
15.
go back to reference Markowitz SD, Bertagnolli MM (2009) Molecular basis of colorectal cancer. N Engl J Med 361:2449–60PubMedCrossRef Markowitz SD, Bertagnolli MM (2009) Molecular basis of colorectal cancer. N Engl J Med 361:2449–60PubMedCrossRef
16.
go back to reference Buhmeida A, Elzagheid A, Algars A et al (2008) Expression of the cell-cell adhaesion molecule β-catenin in colorectal carcinomas and their metastasis. APMIS 116:1–9PubMedCrossRef Buhmeida A, Elzagheid A, Algars A et al (2008) Expression of the cell-cell adhaesion molecule β-catenin in colorectal carcinomas and their metastasis. APMIS 116:1–9PubMedCrossRef
17.
go back to reference Hugh TJ, Dillon SA, Taylor BA et al (1999) Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 80:1046–1051PubMedCrossRef Hugh TJ, Dillon SA, Taylor BA et al (1999) Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 80:1046–1051PubMedCrossRef
18.
go back to reference Pancione M, Forte N, Sabatino L et al (2009) Reduced β-catenin and peroxisome proliferator-activated receptor gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor associated macrophages, cyclooxigenase 2 and patient outcome. Hum Pathol 40:714–725PubMedCrossRef Pancione M, Forte N, Sabatino L et al (2009) Reduced β-catenin and peroxisome proliferator-activated receptor gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor associated macrophages, cyclooxigenase 2 and patient outcome. Hum Pathol 40:714–725PubMedCrossRef
19.
go back to reference Wong SCC, Lo ESF, Chan AKC et al (2003) Nuclear β-catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. J Clin Pathol Mol Pathol 56:347–352CrossRef Wong SCC, Lo ESF, Chan AKC et al (2003) Nuclear β-catenin as a potential prognostic and diagnostic marker in patients with colorectal cancer from Hong Kong. J Clin Pathol Mol Pathol 56:347–352CrossRef
20.
go back to reference Wong SCC, Lo ESF, Chan AKC et al (2004) Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10:1401–1408PubMedCrossRef Wong SCC, Lo ESF, Chan AKC et al (2004) Prognostic and diagnostic significance of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 10:1401–1408PubMedCrossRef
21.
go back to reference Tatsuguchi A, Kishida T, Fujimori S et al (2006) Differential expression of cyclo-oxigenase-2 and nuclear β-catenin in colorectal cancer tissue. Aliment Pharm Therap 24:153–159CrossRef Tatsuguchi A, Kishida T, Fujimori S et al (2006) Differential expression of cyclo-oxigenase-2 and nuclear β-catenin in colorectal cancer tissue. Aliment Pharm Therap 24:153–159CrossRef
22.
go back to reference Horst D, Kriegl L, Engel J et al (2009) CD133 and nuclear β-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034–2040PubMedCrossRef Horst D, Kriegl L, Engel J et al (2009) CD133 and nuclear β-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45:2034–2040PubMedCrossRef
23.
go back to reference Nosho K, Yamamoto H, Takahashi T et al (2007) Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28:1364–1370PubMedCrossRef Nosho K, Yamamoto H, Takahashi T et al (2007) Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 28:1364–1370PubMedCrossRef
24.
go back to reference Resnick MB, Routhier J, Konkin T et al (2004) Epidermal growth factor receptor, c-met, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10:3069–3075PubMedCrossRef Resnick MB, Routhier J, Konkin T et al (2004) Epidermal growth factor receptor, c-met, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10:3069–3075PubMedCrossRef
25.
go back to reference Hoos A, Nissan A, Stojadinovic A et al (2002) Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 8:3841–3849PubMed Hoos A, Nissan A, Stojadinovic A et al (2002) Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res 8:3841–3849PubMed
26.
go back to reference Kallioniemi OP, Wagner U, Kononen J et al (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10:657–662PubMedCrossRef Kallioniemi OP, Wagner U, Kononen J et al (2001) Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10:657–662PubMedCrossRef
27.
go back to reference Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRef Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844–847PubMedCrossRef
28.
go back to reference Egervari K, Szollosi Z, Nemes Z (2007) Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203:169–177PubMedCrossRef Egervari K, Szollosi Z, Nemes Z (2007) Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203:169–177PubMedCrossRef
29.
go back to reference Sapino A, Marchio C, Senetta R et al (2006) Routine assesment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449:288–96PubMedCrossRef Sapino A, Marchio C, Senetta R et al (2006) Routine assesment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449:288–96PubMedCrossRef
30.
go back to reference Fernebro E, Bendhal P, Dictor M et al (2004) Immunohistochemical patterns in rectal cancer: applications of tissue microarray with prognostic correlations. Int J Cancer 111:921–928PubMedCrossRef Fernebro E, Bendhal P, Dictor M et al (2004) Immunohistochemical patterns in rectal cancer: applications of tissue microarray with prognostic correlations. Int J Cancer 111:921–928PubMedCrossRef
31.
go back to reference Xie D, Sham JST, Zeng WF et al (2003) Heterogenous expression and assiciation of β-catenin, p16, and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107:896–902PubMedCrossRef Xie D, Sham JST, Zeng WF et al (2003) Heterogenous expression and assiciation of β-catenin, p16, and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 107:896–902PubMedCrossRef
32.
go back to reference Su Y, Shrubsole MJ, Ness RM et al (2006) Immunohistochemical expression of Ki-67, Cyclin D1, β-catenin, cyclooxygenase-2 and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarray. Cancer Epidem Biomar 15:1719–1726CrossRef Su Y, Shrubsole MJ, Ness RM et al (2006) Immunohistochemical expression of Ki-67, Cyclin D1, β-catenin, cyclooxygenase-2 and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarray. Cancer Epidem Biomar 15:1719–1726CrossRef
33.
go back to reference Bandapalli OR, Dihlmann S, Helwa R et al (2009) Transcriptional activation of the β-catenin gene at the invasion front of colorectal liver metastasis. J Pathol 218:370–379PubMedCrossRef Bandapalli OR, Dihlmann S, Helwa R et al (2009) Transcriptional activation of the β-catenin gene at the invasion front of colorectal liver metastasis. J Pathol 218:370–379PubMedCrossRef
34.
go back to reference Da Silva L, Parry S, Reid L et al (2008) Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32:773–783PubMedCrossRef Da Silva L, Parry S, Reid L et al (2008) Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 32:773–783PubMedCrossRef
35.
go back to reference Muta H, Noguchi M, Kanai Y et al (1996) E-cadherin gene mutations in signet ring cell carcinoma of stomach. Jpn J Cancer Res 87:843–848PubMedCrossRef Muta H, Noguchi M, Kanai Y et al (1996) E-cadherin gene mutations in signet ring cell carcinoma of stomach. Jpn J Cancer Res 87:843–848PubMedCrossRef
36.
go back to reference Kapiteijn E, Liefers GJ, Los LC et al (2001) Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171–178PubMedCrossRef Kapiteijn E, Liefers GJ, Los LC et al (2001) Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 195:171–178PubMedCrossRef
Metadata
Title
Investigation of β-catenin and E-cadherin Expression in Dukes B2 Stage Colorectal Cancer with Tissue Microarray Method. Is It a Marker of Metastatic Potential in Rectal Cancer?
Authors
László Tóth
Csilla András
Csaba Molnár
Miklós Tanyi
Zoltán Csiki
Péter Molnár
János Szántó
Publication date
01-04-2012
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9463-y

Other articles of this Issue 2/2012

Pathology & Oncology Research 2/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine